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Background An avian-like H1N1 swine influenza virus (SIV) is
enzootic in swine populations of Western Europe. The virus is
antigenically distinct from H1N1 SIVs in North America that have
a classical swine virus-lineage H1 hemagglutinin, as does the
pandemic (H1N1) 2009 virus. However, the significance of this
antigenic difference for cross-protection among pigs remains
unknown.
Objectives We examined protection against infection with a
North American triple reassortant H1N1 SIV
[A ⁄ swine ⁄ Iowa ⁄H04YS2 ⁄ 04 (sw ⁄ IA ⁄ 04)] in pigs infected with a
European avian-like SIV [A ⁄ swine ⁄Belgium ⁄ 1 ⁄ 98 (sw ⁄B ⁄ 98)]
4 weeks earlier. We also examined the genetic relationships and
serologic cross-reactivity between both SIVs and with a pandemic
(H1N1) 2009 virus [A ⁄California ⁄ 04 ⁄ 09 (Calif ⁄ 09)].
Results After intranasal inoculation with sw ⁄ IA ⁄ 04, all previously
uninfected control pigs showed nasal virus excretion, high virus
titers in the entire respiratory tract at 4 days post-challenge
(DPCh) and macroscopic lung lesions. Most pigs previously
infected with sw ⁄B ⁄ 98 tested negative for sw ⁄ IA ⁄ 04 in nasal
swabs and respiratory tissues, and none had lung lesions. At
challenge, these pigs had low levels of cross-reactive virus
neutralizing and neuraminidase inhibiting (NI) antibodies to
sw ⁄ IA ⁄ 04, but no hemagglutination-inhibiting antibodies. They
showed similar antibody profiles when tested against Calif ⁄ 09, but
NI antibody titers were higher against Calif ⁄ 09 than sw ⁄ IA ⁄ 04,
reflecting the higher genetic homology of the sw ⁄B ⁄ 98
neuraminidase with Calif ⁄ 09.
Conclusions Our data indicate that immunity induced by
infection with European avian-like H1N1 SIV affords protection
for pigs against North American H1N1 SIVs with a classical H1,
and they suggest cross-protection against the pandemic (H1N1)
2009 virus.
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Introduction
Influenza viruses of H1N1, H3N2 and H1N2 subtypes are
enzootic in swine populations worldwide, but they show
different genetic and antigenic constellations in different
parts of the world.1 The complex epidemiology of swine
influenza viruses (SIVs) is well illustrated by the nature of
H1N1 SIVs in North America versus Europe. In North
America, viruses of the ‘classical swine’ H1N1 lineage were
the predominant SIVs until 1998. These viruses are descen-
dants of the first SIV isolated in 1930 and are related to
the 1918 human pandemic H1N1 virus. Since 1998, reas-
sortant H3N2 SIVs with genes of classical swine, avian and
human influenza virus origin have become established in
the swine population in North America. These viruses fur-
ther reassorted with co-circulating classical H1N1 SIVs
leading to the current triple reassortant H1N1 SIVs that
contain a classical swine-lineage H1 hemagglutinin (HA).2
In Europe, the prevailing H1N1 SIV is of entirely avian
origin and therefore designated ‘avian-like’ H1N1. It was
introduced from wild ducks into the pig population in
1979 and has become the dominant H1N1 European SIV
strain.3,4 Surveillance studies show high seroprevalence
rates for avian-like H1N1 SIVs in swine-dense regions of
Western Europe. In Belgium, for example, 81% of sows
and 42% of fattening pigs tested positive for antibodies.5,6
In Asia, multiple H1N1 lineages appear to circulate, includ-
ing avian-like, classical swine-lineage and triple reassortant
H1N1 SIVs.7,8 Reassortment between the avian-like and tri-
ple reassortant SIV lineages has been occasionally reported
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in Thailand and China.8–10 From May 2009 to May 2010,
the pandemic (H1N1) 2009 influenza virus has been
reported in swine in 22 countries in five continents.11 This
pandemic virus is as a reassortant of at least two circulating
SIVs. Six gene segments, including the classical H1 HA,
originate from North American triple reassortant SIVs,
while the genes encoding the neuraminidase (NA) and
matrix (M) proteins are closely related to those in Euro-
pean and ⁄or Asian avian-like SIVs.12 The emergence of the
pandemic (H1N1) 2009 influenza virus further complicates
the SIV epidemiology.
The HAs of avian-like and classical swine-lineage H1N1
SIVs are serologically distinct when compared by antigenic
analyses with monoclonal antibodies.13,14 Sequence align-
ment of the HA1 regions of the HA gene of these viruses
likewise revealed several amino acid substitutions at puta-
tive antigenic sites.14 The significance of these differences
for cross-protection remains unknown, and there are no
published cross-protection studies with H1N1 SIVs of dif-
ferent lineages in pigs. In this study, we aimed to examine
a) to what extent immunity to a European avian-like
H1N1 SIV may protect pigs from infection with a North
American triple reassortant H1N1 SIV and b) the antigenic
and genetic relationships between both viruses. In an
attempt to extrapolate our findings to protection against
the pandemic (H1N1) 2009 virus, a prototype pandemic
virus was also included in the genetic and antigenic
analyses.
Materials and methods
Viruses and sequence analysis
A ⁄ swine ⁄Belgium ⁄ 1 ⁄ 98 (sw ⁄B ⁄ 98) is representative of pre-
vailing avian-like H1N1 SIVs in Western Europe (GenBank
accession numbers ACN 67524–28).15 A ⁄ swine ⁄ Iowa ⁄
H04YS2 ⁄ 2004 (sw ⁄ IA ⁄ 04) is a triple reassortant H1N1 SIV
belonging to the North American ‘H1ß (rH1N1-like)’ SIV
cluster (GenBank accession numbers GQ452235–42).16
A ⁄California ⁄ 04 ⁄ 09 (Calif ⁄ 09) is a prototype human pan-
demic (H1N1) 2009 virus (GenBank accession numbers
ACP 41102–11).12
The HA, NA, matrix (M1) and nucleoprotein (NP) of the
3 viruses were compared at the nucleotide and protein level
by BLAST software (NCBI). Amino acid (aa) differences at
putative antigenic sites of the HA, as defined by Brownlee
and Fodor,17 were identified by alignment (CLC Sequence
Viewer 6) with the PR8 H1 reference strain. In total, 327 aa
residues (H1 open reading frame numbering) were exam-
ined with special attention to 50 aa located at putative anti-
genic sites. Amino acid differences in the NA were identified
by multiple alignment. In total, 469 NA aa residues were
examined of which 195 were located in antigenic domains as
described by Maurer-Stroh and co-workers.18
Experimental design
Twenty-five 6-week-old pigs from a conventional herd with
a high health status and free of influenza A virus were
used. The pigs were also serologically negative for porcine
reproductive and respiratory syndrome virus and for por-
cine circovirus type 2. Pigs were randomly assigned to three
groups. Two groups were inoculated initially with sw ⁄B ⁄ 98
or sw ⁄ IA ⁄ 04 and challenged 4 weeks later with sw ⁄ IA ⁄ 04
(sw ⁄B ⁄ 98-sw ⁄ IA ⁄ 04, n = 8 and sw ⁄ IA ⁄ 04-sw ⁄ IA ⁄ 04,
n = 8). The third group served as a challenge control group
and was challenged with sw ⁄ IA ⁄ 04 along with the
previously sw ⁄B ⁄ 98 or sw ⁄ IA ⁄ 04 inoculated pigs
(sw ⁄ IA ⁄ 04-control, n = 9). All inoculations were performed
intranasally at 7Æ0 log10 egg infective doses 50% (EID50).
Inoculations were performed on unanesthetized animals.
Pigs were held in a vertical position with the neck
stretched. The inoculum was gradually instilled into the
middle nasal cavity by insertion of a 15-mm plastic cannula
attached to a syringe. All pigs were monitored daily for
clinical signs from 5 days before until 7 days after initial
inoculation (DPI), and from 5 days before until 7 days
after challenge (DPCh), or until euthanasia. A daily clinical
score was recorded for each pig as follows. A score of 1
each was given for the presence of fever (rectal temperature
‡40Æ0!C), depression, tachypnea (respiratory rate ‡45 per
minute), dyspnea and forced abdominal respiration, result-
ing in a minimum clinical score of 0 and a maximum score
of 5 per pig. To obtain the group clinical score per day,
the individual scores of each day were added and divided
by the maximum score possible (i.e. 40 for sw ⁄B ⁄ 98-
sw ⁄ IA ⁄ 04 and sw ⁄ IA ⁄ 04-sw ⁄ IA ⁄ 04, and 45 for sw ⁄ IA ⁄ 04-
control). To determine the extent of virus excretion after
the initial inoculations and after the challenge with
sw ⁄ IA ⁄ 04, nasal swabs were collected daily from all pigs
from 0 until 7 DPI, and from 0 until 7 DPCh, or until
euthanasia. The swabs were weighed before and after col-
lection to determine virus titers per 100 mg nasal secre-
tions. To determine the extent of replication of the
sw ⁄ IA ⁄ 04 challenge virus in the respiratory tract, 4 pigs per
group were euthanized at 4 DPCh. Samples of the upper
(nasal mucosa, tonsil and trachea) and lower (left and right
lung) respiratory tract were collected for virus titration.
Blood samples for serological examinations were collected
at the start of the experiment and 4 weeks after the initial
inoculation, i.e. at the time of challenge with sw ⁄ IA ⁄ 04.
The remaining pigs were also bled at 14 and 28 DPCh.
Virus titration
Nasal swab samples from both nostrils were suspended in
1 ml of phosphate-buffered saline (PBS) supplemented with
10% fetal bovine serum, 100 IU ⁄ml penicillin and
100 lg ⁄ml streptomycin and mixed vigorously for 1 hour.
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The medium was collected, clarified by centrifugation and
used for titration. Tissue samples were weighed and ground
in PBS containing 10 IU ⁄ml penicillin and 10 lg ⁄ml strep-
tomycin to obtain 10% or 20% (w ⁄ v) tissue homogenates.
The homogenates were clarified by centrifugation and used
for titration. All samples were titrated on Madin–Darby
canine kidney (MDCK) cells in serum-free medium with
trypsin (10 lg ⁄ml from porcine pancreas). Briefly, MDCK
cells were seeded in 96-well cell culture plates at a concen-
tration of 250 000 cells per ml. After 3 days of incubation,
the cells were 100% confluent and were inoculated with
10-fold dilutions of the samples using 4 wells per dilution.
MDCK cells were observed daily for cytopathic effect until
7 days after inoculation. Virus titers were calculated by the
method of Reed and Muench.19
Serological assays
Antibody titers against sw ⁄B ⁄ 98, sw ⁄ IA ⁄ 04 and Calif ⁄ 09
were determined in all sera by hemagglutination inhibition
(HI), virus neutralization (VN) and neuraminidase inhibi-
tion (NI) assays, according to standard methods.20,21 Before
use, all sera were heat inactivated (56!C, 30 minutes). In
the HI assay, sera were pre-treated with receptor-destroying
enzyme from Vibrio cholerae and adsorbed onto chicken
erythrocytes. Twofold serum dilutions were incubated
[1 hour, room temperature (RT)] with four hemagglutinat-
ing units of the respective viruses. Finally, 0Æ5% chicken
erythrocytes were added, and the assay was read after 1 h
at RT. In the VN assay, twofold serum dilutions were incu-
bated (1 hour, 37!C) with 100 TCID50 of MDCK-adapted
virus in microtiter plates. MDCK cells were added at a con-
centration of 600000 cells per ml. After incubation
(24 hour, 37!C), the cells were fixed with 4% paraformal-
dehyde. Virus-positive cells were demonstrated by an imm-
unoperoxidase staining using mouse monoclonal antibodies
against influenza A virus nucleoprotein (HB65) and peroxi-
dase-conjugated goat anti-mouse IgG. In the NI assay,
standard virus doses were selected by an assay of NA activ-
ity based on the colorimetric analysis of sialic acid release
from fetuin substrate. Twofold serum dilutions were incu-
bated with the standard virus dilution in microtiter plates,
and the reduction of NA activity in each serum dilution
was compared with that in controls without serum. All sera
were tested in duplicate, and antibody titers were expressed
as the reciprocal of the highest serum dilution that com-
pletely inhibited hemagglutination or virus replication in
MDCK cells, or that gave a 50% inhibition of NA activity.
Starting dilutions were 1:2 in the VN test, and 1:10 in the
HI and NI tests.
Statistical analysis
Differences in serum HI, VN and NI antibody titers were
compared between groups in two-sample Student’s t-tests.
Samples that tested negative in the serological assays were
given a value corresponding to half of the minimum
detectable antibody titer. P < 0Æ05 was taken as the level of
statistical significance.
Results
Genetic and antigenic relationships between
sw ⁄B ⁄98, sw ⁄ IA ⁄04 and Calif ⁄09
Percentages of nucleotide and aa identity between the 4
analyzed genes of sw ⁄B ⁄ 98 and sw ⁄ IA ⁄ 04 or Calif ⁄ 09 are
shown in Table 1. Nucleotide sequence identity of the HA
gene of sw ⁄B ⁄ 98 and the 2 viruses with the classical swine-
lineage HA (sw ⁄ IA ⁄ 04 and Calif ⁄ 09) was low (74–75%),
whereas both classical HAs were more similar (91%).
Nucleotide sequences of the NA and M1 genes of sw ⁄B ⁄ 98
were more similar to Calif ⁄ 09 (92% and 95%, respectively)
than to sw ⁄ IA ⁄ 04 (79% and 88%, respectively), consistent
with the Eurasian virus phylogenetic lineage of these 2
genes in the 2009 pandemic viruses. All viruses were
equally similar in the NP gene (83%). Similar but generally
higher relationships were observed at the aa level.
Amino acid changes at presumed antigenic sites of the
HA are shown in Figure 1. The HA1 segment of sw ⁄B ⁄ 98
contained 76 aa differences compared to sw ⁄ IA ⁄ 04 and
84 aa differences with Calif ⁄ 09, and respectively 13 and 14
changes were in aa residues at putative antigenic sites. The
HA1 regions of the viruses with the classical swine-lineage
HA genes were more closely related (39 aa differences, with
8 at putative antigenic sites). The NA gene of sw ⁄B ⁄ 98 was
more closely related to Calif ⁄ 09 (28 aa differences, with 12
at putative antigenic sites) than to sw ⁄ IA ⁄ 04 (82 aa differ-
ences, with 27 at putative antigenic sites). The NA of
sw ⁄ IA ⁄ 04 and Calif ⁄ 09 was different in 83 aa residues, of
which 31 were located at putative antigenic sites.
Table 1. Percent identity of the nucleotide and amino acid
sequences of the hemagglutinin (HA), neuraminidase (NA), matrix
(M) and nucleoprotein (NP) genes of sw ⁄ B ⁄ 98 with those of
sw ⁄ IA ⁄ 04 or a prototype pandemic (H1N1) 2009 virus
% identity compared to sw ⁄ B ⁄ 98
HA NA M1 NP
N aa N aa N aa N aa
Sw ⁄ IA ⁄ 04 75 75 79 82 88 94 83 98
Calif ⁄ 09 74 72 92 93 95 98 83 97
N, nucleotide; aa, amino acid.
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Virus excretion and serological response after
initial infection with sw ⁄B ⁄98 or sw ⁄ IA ⁄04
Mild fever (40Æ4–40Æ8!C) was seen in all pigs 1 and 2 days
after inoculation with sw ⁄B ⁄ 98 (clinical scores 0Æ30 and
0Æ20 on 1 and 2 DPI, respectively), and in most pigs after
initial inoculation with sw ⁄ IA ⁄ 04 (clinical scores 0Æ20 and
0Æ10 on 1 and 2 DPI, respectively), but respiratory signs
were absent. All inoculated pigs excreted the SIVs used for
inoculation for 6 consecutive DPI. Mean virus titers in
nasal swabs are shown in Figure 2. The challenge control
pigs remained virus negative.
All pigs were negative in antibody assays at the start of
the experiments against all three viruses. Serological find-
ings at the time of challenge with sw ⁄ IA ⁄ 04, i.e. 4 weeks
after initial inoculation, are shown in Table 2. As expected,
all control pigs were seronegative at the time of challenge,
whereas all pigs inoculated previously with either sw ⁄ IA ⁄ 04
or sw ⁄B ⁄ 98 had HI, VN and NI antibodies to the SIV used
for inoculation. In addition, most pigs inoculated with
sw ⁄ IA ⁄ 04 had HI antibodies that cross-reacted with
sw ⁄B ⁄ 98 and ⁄or Calif ⁄ 09, and all these pigs had cross-reac-
tive VN and NI antibodies to the other two viruses. Cross-
Figure 1. Alignment of deduced amino acid
sequences at antigenic sites, as defined by
Brownlee and Fodor,17 of the hemagglutinins
of sw ⁄ B ⁄ 98, sw ⁄ IA ⁄ 04 and Calif ⁄ 09. Only
the amino acids different from those in the
sw ⁄ B ⁄ 98 sequence are indicated, and
conserved residues are shown as dashes.
Figure 2. Nasal virus excretion after initial
inoculation and after challenge with
sw ⁄ IA ⁄ 04. Mean virus titers in nasal swabs of
each group are given. Sw ⁄ B ⁄ 98-sw ⁄ IA ⁄ 04,
sw ⁄ IA ⁄ 04-sw ⁄ IA ⁄ 04 and sw ⁄ IA ⁄ 04-control
groups are represented by dotted, dashed
and full lines, respectively. The thin dashed
line represents the detection limit (<1Æ7 log10
TCID50 ⁄ 100 mg).
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reactive HI, VN and NI antibody titers to both hetero-
logous viruses were significantly lower than those to the
homologous virus (P < 0Æ05). All pigs inoculated with
sw ⁄B ⁄ 98 lacked cross-reactive HI antibodies to sw ⁄ IA ⁄ 04
and Calif ⁄ 09, but most of them had cross-reactive VN anti-
bodies to both viruses, though at lower titers than to the
homologous virus (P < 0Æ05). Cross-reactive NI antibodies
against both viruses were found in all pigs, and they were
higher to Calif ⁄ 09 than to sw ⁄ IA ⁄ 04 (P < 0Æ05).
Clinical and virological protection after challenge
with sw ⁄ IA ⁄04
After subsequent challenge with sw ⁄ IA ⁄ 04, mild fever
(40Æ6–40Æ1!C), depression and respiratory signs were seen
in the previously uninfected control pigs at 1 (clinical score
0Æ44) and 2 (clinical score 0Æ17) DPCh only. Mean virus
titers in nasal swabs are shown in Figure 2. All previously
uninfected control pigs excreted the sw ⁄ IA ⁄ 04 challenge
virus at high titers (up to 7Æ5 log10 TCID50 ⁄ 100 mg) for 6
consecutive DPCh or until euthanasia at 4 DPCh, whereas
disease and virus excretion were undetectable in the
sw ⁄ IA ⁄ 04-sw ⁄ IA ⁄ 04 group. Interestingly, only 1 of 8 pigs
inoculated previously with sw ⁄B ⁄ 98 had mild fever (40Æ0–
40Æ1!C) at 1 and 2 DPCh with sw ⁄ IA ⁄ 04 (clinical score
0Æ03 on both days). Likewise, only 2 of 8 pigs of the
sw ⁄B ⁄ 98-sw ⁄ IA ⁄ 04 group had detectable nasal virus excre-
tion, and nasal virus titers were lower and detectable for a
shorter duration than in the previously uninfected control
group. One pig tested positive at 3 DPCh (3Æ0 log10
TCID50 ⁄ 100 mg) only, and one pig (nr V-09-949) on 2, 3
and 4 DPCh (1Æ7, 3Æ0 and 2Æ3 log10 TCID50 ⁄ 100 mg,
respectively).
Sw ⁄ IA ⁄ 04 virus titers in the respiratory tract of the pigs
euthanized at 4 DPCh are shown in Table 3. Sw ⁄ IA ⁄ 04 was
recovered from the nasal mucosa, tonsil, trachea, left lung
and right lung of all 4 previously uninfected control pigs.
Table 2. Serological findings at the time of challenge with sw ⁄ IA ⁄ 04 and 2 weeks later in naı¨ve control pigs and sw ⁄ B ⁄ 98 or sw ⁄ IA ⁄ 04-immune
pigs
Group Test
Mean antibody titers of positive pigs ± SEM* (number of positive pigs ⁄ total number of pigs)
Time of challenge 14 DPCh
sw ⁄ B ⁄ 98 sw ⁄ IA ⁄ 04 Calif ⁄ 09 sw ⁄ B ⁄ 98 sw ⁄ IA ⁄ 04 Calif ⁄ 09
sw ⁄ IA ⁄ 04- control HI <! < < 18 ± 2 (5 ⁄ 5) 68 ± 12 (5 ⁄ 5) 10 ± 0 (2 ⁄ 5)
VN < < < 46 ± 15 (5 ⁄ 5) 154 ± 33 (5 ⁄ 5) 12 ± 3 (5 ⁄ 5)
NI < < < 22 ± 7 (5 ⁄ 5) 288 ± 93 (5 ⁄ 5) 16 ± 6 (5 ⁄ 5)
sw ⁄ IA ⁄ 04-sw ⁄ IA ⁄ 04 HI 16 ± 2 (7 ⁄ 8) 88 ± 22 (8 ⁄ 8) 15 ± 2 (4 ⁄ 8) 15 ± 3 (4 ⁄ 4) 45 ± 13 (4 ⁄ 4) 15 ± 4 (2 ⁄ 4)
VN 44 ± 13 (8 ⁄ 8) 180 ± 26 (8 ⁄ 8) 9 ± 2 (8 ⁄ 8) 75 ± 40 (4 ⁄ 4) 208 ± 31 (4 ⁄ 4) 27 ± 14 (4 ⁄ 4)
NI 25 ± 6 (8 ⁄ 8) 355 ± 91 (8 ⁄ 8) 16 ± 4 (8 ⁄ 8) 30 ± 6 (4 ⁄ 4) 280 ± 40 (4 ⁄ 4) 23 ± 6 (4 ⁄ 4)
sw ⁄ B ⁄ 98-sw ⁄ IA ⁄ 04 HI 135 ± 31 (8 ⁄ 8) < < 120 ± 23 (4 ⁄ 4) 40 ± 14 (4 ⁄ 4) 17 ± 3 (3 ⁄ 4)
VN 416 ± 82 (8 ⁄ 8) 8 ± 2 (7 ⁄ 8) 3 ± 1 (7 ⁄ 8) 1216 ± 352 (4 ⁄ 4) 128 ± 23 (4 ⁄ 4) 32 ± 6 (4 ⁄ 4)
NI 230 ± 70 (8 ⁄ 8) 29 ± 4 (8 ⁄ 8) 68 ± 15 (8 ⁄ 8) 800 ± 160 (4 ⁄ 4) 400 ± 139 (4 ⁄ 4) 720 ± 201 (4 ⁄ 4)
*Standard error of the mean; !antibody titers below detection limits, i.e. <10 in HI and NI tests and <2 in VN test. HI, hemagglutination inhibition;
NI, neuraminidase inhibition; VN, virus neutralization.
Table 3. Virus titers in the respiratory tract 4 days after challenge with sw ⁄ IA ⁄ 04 in naı¨ve control pigs and sw ⁄ B ⁄ 98 or sw ⁄ IA ⁄ 04-immune pigs
Group
Range of virus titers (log10 TCID50 ⁄ g) of positive pigs (number of positive pigs ⁄ total number of pigs)
Nasal mucosa
respiratory part
Nasal mucosa
olfactory part Tonsil Trachea Left lung Right lung
sw ⁄ IA ⁄ 04-control 4Æ1–6Æ6 (4 ⁄ 4) 4Æ3–6Æ0 (4 ⁄ 4) 4Æ0–5Æ0 (4 ⁄ 4) 5Æ5–6Æ5 (4 ⁄ 4) 6Æ3–6Æ7 (4 ⁄ 4) 6Æ2–7Æ2 (4 ⁄ 4)
sw ⁄ IA ⁄ 04-sw ⁄ IA ⁄ 04 <* < < < < <
sw ⁄ B ⁄ 98-sw ⁄ IA ⁄ 04 < < < 2Æ0 (1 ⁄ 4) < <
*Virus titers below the detection limit (1Æ9 log10 TCID50 ⁄ g for nasal mucosa, tonsil and trachea; 1Æ7 log10TCID50 ⁄ g for lung) in all pigs.
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Virus titers ranged from 4Æ0 to 6Æ6 log10 TCID50 ⁄ g in the
upper respiratory tract, and from 6Æ3 to 7Æ2 log10 TCID50 ⁄ g
in the lungs. All four pigs of the sw ⁄ IA ⁄ 04-sw ⁄ IA ⁄ 04 group
were completely virus negative. In the sw ⁄B ⁄ 98-sw ⁄ IA ⁄ 04
group, only pig nr V-09-949 tested positive, and this was
only in the tracheal sample and only at a low titer of
2Æ0 log10 TCID50 ⁄ g. Areas of lung consolidation, involving
5–38% of the lung surface, were present in the four previ-
ously uninfected control pigs euthanized, but absent in the
pigs from the other groups.
Serological profile after challenge with sw ⁄ IA ⁄04
Serological findings at 14 DPCh are shown in Table 2. All
previously uninfected control pigs seroconverted (i.e. ‡4-
fold increase in antibody titer) to sw ⁄ IA ⁄ 04 after challenge
infection and developed cross-reactive HI, VN and NI anti-
body titers to both other viruses, though at lower titers
than the homologous sw ⁄ IA ⁄ 04 titers. Only two pigs, how-
ever, developed HI antibodies to Calif ⁄ 09. In the
sw ⁄ IA ⁄ 04-sw ⁄ IA ⁄ 04 group, HI, VN and NI antibody titers
to the three viruses were comparable to those before chal-
lenge (P > 0Æ05). In the sw ⁄B ⁄ 98-sw ⁄ IA ⁄ 04 pigs, antibody
titers to sw ⁄B ⁄ 98 did not change after challenge (P > 0Æ05).
Antibody titers to sw ⁄ IA ⁄ 04 and sw ⁄Calif ⁄ 09 increased, but
only the increases in VN antibody titers to sw ⁄ IA ⁄ 04, and
VN and NI antibody titers to Calif ⁄ 09 were significant
(P < 0Æ05). Antibody titers at 28 DPCh were similar to
those at 14 DPCh (P > 0Æ05).
Discussion
This study shows a stronger than expected protection
against infection with a North American triple reassortant
H1N1 SIV in pigs infected with a phylogenetically distinct
European avian-like SIV 4 weeks earlier. It has long been
known that the HA1 of both virus lineages shows consider-
able antigenic and genetic differences.13,14,22 Cross-reactive
HI antibodies against viruses with a classical H1 are usually
only detectable in high titered or hyperimmune antisera
against avian-like H1N1 SIV, and not in lower titered post-
infection swine sera.3,16,23 The VN test detects a broader
range of neutralizing antibodies than the HI test,24 which
likely explains the cross-reactive VN antibody titers in our
study. Du¨rrwald et al.25 detected cross-reactive VN anti-
bodies against German isolates of the pandemic 2009
(H1N1) virus in pigs experimentally infected with the
avian-like H1N1 SIV A ⁄ swine ⁄Haselu¨nne ⁄ IDT2617 ⁄ 2003,
which is in agreement with our findings. The cross-protec-
tion between European and North American H1N1 SIVs
was clearly stronger than that observed between European
H1N1 and H1N2 SIVs in previous experimental stud-
ies.20,26,27 In those prior studies, the pigs were first inocu-
lated with sw ⁄B ⁄ 98 followed 4 weeks later by
sw ⁄Gent ⁄ 7625 ⁄ 99, a typical European H1N2 virus. One of
these studies used the same intranasal inoculation route
and dose as in the present experiment.27 This resulted in
high H1N2 virus titers in nasal swabs of all challenge con-
trol pigs during 6 consecutive DPCh. All pigs that had been
previously infected with sw ⁄B ⁄ 98 also shed high amounts
of H1N2 virus in nasal swabs, and the duration of excre-
tion was only 1 or 2 days shorter than in the control
group. This contrasts with the excretion of the North
American H1N1 SIV in the present study, which was lar-
gely blocked in sw ⁄B ⁄ 98-immune pigs. The inferior protec-
tion against the H1N2 virus may relate to its more distant
relationship to both the NA and HA of sw ⁄B ⁄ 98 when
compared with the North American H1N1 SIV. Indeed, the
HA of sw ⁄Gent ⁄ 7625 ⁄ 99 (H1N2) shows only 70Æ5%
sequence homology with sw ⁄B ⁄ 98 (H1N1) and as much as
28 aa differences in antigenic sites, versus 75% homology
and 13 aa changes in antigenic sites for sw ⁄ IA ⁄ 04 (H1N1).
This translates into detectable cross-reactive VN and NI
antibodies to the antigenically more closely related H1N1
virus, but not to H1N2.20,27 The NP and M proteins, which
are major targets for T cells, show more than 95% nucleo-
tide identity between European H1N1 and H1N2 SIVs,26
but they remain relatively conserved in the North American
H1N1 SIV. Based on these findings and on general knowl-
edge of the cross-protective immune response between
influenza viruses,28 we believe that the observed cross-pro-
tection between antigenically distinct H1N1 SIVs in the
present study results from a combination of antibody- and
cell-mediated immune (CMI) responses to multiple viral
proteins. In addition, mucosal as well as systemic immunity
is likely involved. Most important, our data provide further
proof of the concept that cross-protection can occur
between influenza viruses with multiple aa differences in
three of four antigenic sites of the HA, and in the absence
of detectable cross-reactive serum HI antibody.
Our data further support the concept advanced previ-
ously16 that the immune response after infection with avian-
like European H1N1 SIV may also protect pigs against the
pandemic (H1N1) 2009 virus. Our genetic data and serologic
results agree with previous findings about the swine ancestry
of the pandemic virus.10,12 The HA and NP of the pandemic
Calif ⁄ 09 isolate were closely related to the North American
sw ⁄ IA ⁄ 04 SIV, and both viruses shared many aa changes at
antigenic sites of the HA, compared to the European
sw ⁄B ⁄ 98 SIV. The NA and M1 of the pandemic virus, in con-
trast, were phylogenetically derived from Eurasian-lineage,
avian-like SIV.12 This was reflected in higher NI antibody
titers to the pandemic virus than to the North American
challenge H1N1 SIV in pigs immune to sw ⁄B ⁄ 98. It is there-
fore rational to expect an even more solid cross-protection
against the pandemic virus than to sw ⁄ IA ⁄ 04-like North
American swine viruses in response to prior infection with
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sw ⁄B ⁄ 98-like European viruses, though this assumption
needs to be tested by further challenge studies. In experimen-
tal studies, in influenza naive pigs, the pandemic virus was as
infectious for pigs as the endemic SIVs, and it was readily
transmitted between pigs.29–32 At this time of writing, how-
ever, cases of pandemic (H1N1) 2009 virus in pigs in Europe
have been reported in only 10 countries, and the virus is far
less widespread than the endemic SIVs.11 However, it is strik-
ing that most cases have been reported in countries that were
previously free of SIV, such as Norway,33 and in countries
with a low-to-moderate SIV prevalence, like Ireland and the
United Kingdom.
The extent of cross-protection between any two influenza
viruses may appear greater under experimental than under
natural conditions, because of many possible differences
between the experimental and field situations. As an exam-
ple, the short time interval between the primary influenza
virus inoculation and challenge in our and other studies
represents an artificial situation and may optimize the out-
come of the experiment. On the other hand, fattening pigs
in swine-dense regions of Europe are frequently exposed to
multiple SIV subtypes within their 26-week short lifetime.
For instance, as many as 84Æ5% of fattening swine farms in
Belgium, France, Italy and Spain showed serologic evidence
of infection with 2 or 3 SIV subtypes during 2006–2008.6
Such consecutive or co-infections will likely increase cross-
protection against viruses with a classical H1 HA. Experi-
mental consecutive infections with European H1N1 and
H1N2 viruses were also shown to induce cross-reactive HI
antibody to North American SIVs as well as pandemic
(H1N1) 2009 virus, whereas the respective single infections
failed to do so.16 Such combined H1N1-H1N2 infections
even afforded protection against challenge with H3N2 SIV,
despite no or minimal cross-reactive HI antibody.27 Recent
serological investigations demonstrated cross-reactive HI
antibodies to the pandemic 2009 (H1N1) virus in as much
as 52% of 1559 pig serum samples from 195 German pig
herds.25 The sera had been collected in the mid-2009,
before the first reports of the pandemic virus in European
swine populations. Furthermore, vaccines based on the
endemic European SIVs are licensed in the main pig-pro-
ducing Member States of Europe, but not in countries with
lower pig numbers and SIV prevalences like Norway or Ire-
land. These vaccines seem to offer partial cross-protection
against the pandemic virus.25 All these data further support
the idea that pigs in swine-dense regions of Europe may
experience protection against influenza viruses with a clas-
sical swine-lineage H1.
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